



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Vincasar PFS (vincristine)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:		* Date of Birth:
Office Fax:			* Patient Street Address:		
Office Street Address:			City	State	Zip
City	State	Zip	Patient Phone:		
<b>Urgency:</b>					
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
<b>Medication requested:</b>					
<input type="checkbox"/> Vincasar PFS 1mg/mL vial <input type="checkbox"/> vincristine 1mg/mL vial <input type="checkbox"/> Vincasar PFS 2mg/2mL vial <input type="checkbox"/> vincristine 2mg/2mL vial					
ICD10:		Dose:		Duration of therapy:	
Frequency of therapy:					
<b>Where will this medication be obtained?</b>					
<input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Other (please specify): <b>**Cigna's nationally preferred specialty pharmacy</b>					
<b>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</b>					
<b>Facility and/or doctor dispensing and administering medication:</b>					
Facility Name:		State:		Tax ID#:	
Address (City, State, Zip Code):					
<b>Is the patient a candidate for home infusion?</b> Yes <input type="checkbox"/> No <input type="checkbox"/>					
<b>Does the physician have an in-office infusion site?</b> Yes <input type="checkbox"/> No <input type="checkbox"/>					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>Diagnosis related to use:</b>					
<input type="checkbox"/> acute lymphoblastic leukemia (ALL), including pediatric acute lymphoblastic leukemia <input type="checkbox"/> adult T-cell leukemia/lymphoma (ATLL) <input type="checkbox"/> AIDS-related B-cell lymphoma <input type="checkbox"/> anaplastic glioma <input type="checkbox"/> Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) <input type="checkbox"/> bone cancer including Ewing Sarcoma <input type="checkbox"/> Burkitt lymphoma <input type="checkbox"/> Castleman's disease (CD, giant lymph node hyperplasia, angiofollicular lymph node hyperplasia [AFH]) <input type="checkbox"/> chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) <input type="checkbox"/> diffuse large B-cell lymphoma (DLBCL) <input type="checkbox"/> follicular lymphoma (FL) <input type="checkbox"/> gastric MALT lymphoma <input type="checkbox"/> Gestational Trophoblastic Neoplasia (GTN) <input type="checkbox"/> glioblastoma <input type="checkbox"/> Hepatosplenic Gamma-Delta T-Cell Lymphoma (HGDTCL) <input type="checkbox"/> High-Grade B-Cell Lymphoma			<input type="checkbox"/> Merkel cell carcinoma (MCC) <input type="checkbox"/> neuroendocrine tumors (NET) – pheochromocytoma (PCC)/paraganglioma <input type="checkbox"/> nodal marginal zone lymphoma (NMZL) <input type="checkbox"/> nongastric MALT lymphoma <input type="checkbox"/> ovarian, fallopian tube, or primary peritoneal cancer <input type="checkbox"/> peripheral T-cell lymphoma (PTCL) <input type="checkbox"/> pilocytic astrocytoma <input type="checkbox"/> post-transplant lymphoproliferative disorder (PTLD) <input type="checkbox"/> primary CNS lymphoma <input type="checkbox"/> primary cutaneous CD30+ T-cell lymphoproliferative disorder <input type="checkbox"/> small cell lung cancer (SCLC) <input type="checkbox"/> soft tissue sarcoma (STS) including rhabdomyosarcoma(RMS) <input type="checkbox"/> splenic marginal zone lymphoma (SMZL) <input type="checkbox"/> Squamous Cell Carinoma of the head and neck (SCCHN) including ethmoid sinus, maxillary sinus, very advanced <input type="checkbox"/> supratentorial astrocytoma/oligodendroglioma <input type="checkbox"/> T-cell lymphoma – breast implant-associated ALCL <input type="checkbox"/> thymoma or thymic carcinoma		

- Histologic Transformation of Marginal Zone lymphoma (MZL) to Diffuse Large B-Cell lymphoma (DLBCL)
- Hodgkin's lymphoma (HL)
- Mantle cell lymphoma (MCL)
- medulloblastoma

- Waldenström's macroglobulinemia (WM, lymphoplasmacytic lymphoma)
- Wilms' Tumor
- other (please specify):

**Clinical Information:**

(if DLBCL) Is the drug requested being given every 14 days with rituximab (Rituxan, Ruxience, Truxima), cyclophosphamide, doxorubicin (Hydroxydaunomycin), and prednisone (also known as R-CHOP-14 treatment or dose dense R-CHOP)?

Yes  No

(if PTCL) Is your patient using vincristine (Vincasar PFS) as a part of Hyper CVAD alternating with high-dose methotrexate (MTX) and cytarabine? Note: Hyper CVAD consists of hyperfractionated cyclophosphamide, vincristine [Vincasar PFS], doxorubicin [Adriamycin], and dexamethasone.

Yes  No

**Additional Information:** (please include disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at:** [www.covermymeds.com/main/prior-authorization-forms/cigna/](http://www.covermymeds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v072220

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005